| Name | Title | Contact Details |
|---|
Heritage of Edina Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hutcheson Medical Center is one of the largest community hospitals in Georgia and has been recognized by the Georgia Alliance of Community Hospitals as one of the top community hospitals in Georgia several times.
Saint Peters Healthcare System, Inc. is a New Jersey nonprofit corporation sponsored by the Roman Catholic Diocese of Metuchen. The System consists of Saint Peters University Hospital, Saint Peters Health & Management Services Corporation and The Saint Peters Foundation. Saint Peters Healthcare System was formed in 2007 and reflects the expansive scope of health and wellness services we offer to our community. Our services are offered to all. We are a Catholic institution with a capital C and a small c. We draw inspiration from our religious heritage. Our care for others is universal, extending to those of other faiths and in some cases, of no faith whatsoever. Without question, the fact that ours is a faith-based healthcare delivery system is of primary significance. At Saint Peters Healthcare System, you will find leading-edge technology and an experienced staff. You will also find the trust and compassion that we have always been known for.
Assisted Living-Madison House is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.